Full-Year Total Revenue Growth of 20% to $237.2 Million, with MACI Revenue Growth of 20% and Burn Care Revenue Growth of 22% Full-Year Adjusted EBITDA Growth of 58% to $53.4 Million Record Fourth Quarter Gross Margin of 78%, Adjusted EBITDA Margin of 40%, and Net Income of $19.8 Million Mid-Term Profitability Targets Increased to Gross Margin in the High-70% Range and Adjusted EBITDA Margin in the High-30% Range Strong MACI Arthro Key Launch Indicators, with Approximately 250 MACI Arthro Surgeons Trained to ...

CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its fourth-quarter and full-year 2024 financial results on Thursday, February 27, 2025. Vericel’s management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights. The live webcast can be accessed on the Investor Relations section of th ...

While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock aliv ...

Exhibit 99.2 'VERICEL Advanced Therapies for the Sports Medicine & Severe Burn Care 43RD ANNUAL J.P. MO HEALTHCARE CONFER These and other significant factors are dis in Vericel's Annual Report on Form 10- December 31, 2023, filed with the Se Commission (SEC) on February 29, 202 Report on Form 10-Q for the quarter ende filed with the SEC on November 7, 2024, a the SEC. These forward-looking statement the date hereof and Vericel does not a disclaims any obligation to update any of statements to reflect a chan ...

Full-Year 2024 Total Revenue Growth of 20% and Adjusted EBITDA Growth of Approximately 55% MACI Full-Year 2024 Revenue Growth of 20%, with Fourth Quarter Revenue of $68.2 to $68.7 Million Highest Quarterly MACI Implants, Surgeons, and Biopsies Since Launch and Strong Early MACI Arthro Launch Indicators Record Fourth Quarter Gross Margin of Approximately 77% and Adjusted EBITDA Margin of 39% 2025 Total Revenue Guidance of 20% to 23% Growth Mid-Term Profitability Targets Increased to Gross Margin in the High- ...

CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference at 10:30 a.m. ET (7:30 a.m. PT) on Wednesday, January 15, 2025. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com. About Vericel Corporation Ver ...

We are currently offering a one-month trial into the Biotech Forum at half the regular price. To see what I and the other season biotech investors are targeting as trading ideas in real-time, just join our community at The Biotech Forum by clicking HERE .Today, we take a deeper peak at Vericel Corporation (NASDAQ: VCEL ) whose stock has moved up some 40% in recent months. The company is moving to profitably this fiscal year and is seeing impressive sales growth. That said, after the recent rise in equity, v ...

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the st ...

Core Insights - MannKind Corporation reported strong revenue growth in Q3 2024, indicating a positive performance for the company [5]. Group 1: Company Overview - The conference call featured key participants including Eric Burns (Vice President of Finance & Investor Relations), Nick Colangelo (Chief Executive Officer), and Joe Mara (Chief Financial Officer) [1][2][3]. - The company emphasized the importance of forward-looking statements and the associated risks and uncertainties [4][5]. Group 2: Financial Performance - The company highlighted its outstanding quarter with significant total revenue growth, showcasing its operational success [5].

Company Performance - Vericel Corporation reported a quarterly loss of $0.02 per share, better than the Zacks Consensus Estimate of a loss of $0.05, and an improvement from a loss of $0.08 per share a year ago, representing an earnings surprise of 60% [1] - The company posted revenues of $57.91 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 4.68%, and showing an increase from year-ago revenues of $45.58 million [2] - Over the last four quarters, Vericel has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Performance - Vericel shares have increased approximately 34.9% since the beginning of the year, outperforming the S&P 500's gain of 24.3% [3] - The current consensus EPS estimate for the coming quarter is $0.33 on revenues of $81.48 million, and for the current fiscal year, it is $0.12 on revenues of $240.74 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Vericel belongs, is currently in the top 36% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that industry performance can significantly impact stock performance [5][8]